Ex vivo gene transfer for improvement of transplanted pancreatic islet viability and function

S. Van Linthout, P. Madeddu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Human pancreatic islet transplantation has recently been shown to be successful in replacing pancreatic endocrine function into type I diabetic recipients. A major drawback, however, is the high amount of pancreatic β cells required to render one single patient insulin-independent. Given the shortage of human β cell donors, the majority of type 1 diabetic patients remain excluded from this therapeutic option. High number of islets are requested since substantial islet cell death and dysfunction occur within the first few hours and days after islet transplantation. Impaired vascularization of the engraft, the non-specific inflammatory reaction at the site of transplantation, together with the presence of active or memory autoimmune responses to islet autoantigens and allogeneic recognition contribute to apoptosis of β cells and subsequent early graft function loss. This review will focus on ex vivo engineering of the islet graft by gene transfer to improve islet engraftment. An overview of currently used gene transfer techniques will be given and their potential will be discussed.

Original languageEnglish
Pages (from-to)2927-2940
Number of pages14
JournalCurrent Pharmaceutical Design
Volume11
Issue number22
DOIs
Publication statusPublished - 2005

Fingerprint

Islets of Langerhans
Islets of Langerhans Transplantation
Genes
Transplants
Gene Transfer Techniques
Autoimmunity
Cell Death
Transplantation
Tissue Donors
Insulin
Apoptosis
Transfer (Psychology)
Therapeutics

Keywords

  • Angiogenesis
  • Diabetes
  • Engraftment
  • Ex Vivo gene transfer
  • Islets

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Ex vivo gene transfer for improvement of transplanted pancreatic islet viability and function. / Van Linthout, S.; Madeddu, P.

In: Current Pharmaceutical Design, Vol. 11, No. 22, 2005, p. 2927-2940.

Research output: Contribution to journalArticle

@article{88044e4c2a6b48fdb7efdeb025137958,
title = "Ex vivo gene transfer for improvement of transplanted pancreatic islet viability and function",
abstract = "Human pancreatic islet transplantation has recently been shown to be successful in replacing pancreatic endocrine function into type I diabetic recipients. A major drawback, however, is the high amount of pancreatic β cells required to render one single patient insulin-independent. Given the shortage of human β cell donors, the majority of type 1 diabetic patients remain excluded from this therapeutic option. High number of islets are requested since substantial islet cell death and dysfunction occur within the first few hours and days after islet transplantation. Impaired vascularization of the engraft, the non-specific inflammatory reaction at the site of transplantation, together with the presence of active or memory autoimmune responses to islet autoantigens and allogeneic recognition contribute to apoptosis of β cells and subsequent early graft function loss. This review will focus on ex vivo engineering of the islet graft by gene transfer to improve islet engraftment. An overview of currently used gene transfer techniques will be given and their potential will be discussed.",
keywords = "Angiogenesis, Diabetes, Engraftment, Ex Vivo gene transfer, Islets",
author = "{Van Linthout}, S. and P. Madeddu",
year = "2005",
doi = "10.2174/1381612054546743",
language = "English",
volume = "11",
pages = "2927--2940",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "22",

}

TY - JOUR

T1 - Ex vivo gene transfer for improvement of transplanted pancreatic islet viability and function

AU - Van Linthout, S.

AU - Madeddu, P.

PY - 2005

Y1 - 2005

N2 - Human pancreatic islet transplantation has recently been shown to be successful in replacing pancreatic endocrine function into type I diabetic recipients. A major drawback, however, is the high amount of pancreatic β cells required to render one single patient insulin-independent. Given the shortage of human β cell donors, the majority of type 1 diabetic patients remain excluded from this therapeutic option. High number of islets are requested since substantial islet cell death and dysfunction occur within the first few hours and days after islet transplantation. Impaired vascularization of the engraft, the non-specific inflammatory reaction at the site of transplantation, together with the presence of active or memory autoimmune responses to islet autoantigens and allogeneic recognition contribute to apoptosis of β cells and subsequent early graft function loss. This review will focus on ex vivo engineering of the islet graft by gene transfer to improve islet engraftment. An overview of currently used gene transfer techniques will be given and their potential will be discussed.

AB - Human pancreatic islet transplantation has recently been shown to be successful in replacing pancreatic endocrine function into type I diabetic recipients. A major drawback, however, is the high amount of pancreatic β cells required to render one single patient insulin-independent. Given the shortage of human β cell donors, the majority of type 1 diabetic patients remain excluded from this therapeutic option. High number of islets are requested since substantial islet cell death and dysfunction occur within the first few hours and days after islet transplantation. Impaired vascularization of the engraft, the non-specific inflammatory reaction at the site of transplantation, together with the presence of active or memory autoimmune responses to islet autoantigens and allogeneic recognition contribute to apoptosis of β cells and subsequent early graft function loss. This review will focus on ex vivo engineering of the islet graft by gene transfer to improve islet engraftment. An overview of currently used gene transfer techniques will be given and their potential will be discussed.

KW - Angiogenesis

KW - Diabetes

KW - Engraftment

KW - Ex Vivo gene transfer

KW - Islets

UR - http://www.scopus.com/inward/record.url?scp=22944437744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22944437744&partnerID=8YFLogxK

U2 - 10.2174/1381612054546743

DO - 10.2174/1381612054546743

M3 - Article

VL - 11

SP - 2927

EP - 2940

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 22

ER -